| 1 |
Zhang C, Leighl NB, Wu YL, et al. Emerging therapies for non-small cell lung cancer [J]. J Hematol Oncol, 2019, 12(1): 45-54.
|
| 2 |
吴国明，钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
|
| 3 |
王 园，杨 懿，牟云飞，等. 可切除非小细胞肺癌患者术后奥西替尼靶向治疗分析[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(5): 657-660.
|
| 4 |
Goebel C, Louden CL, McKenna R Jr, et al. Diagnosis of non-small cell lung cancer for early stage asymptomatic patients [J]. Cancer Genomics Proteomics, 2019, 16(4):229-244.
|
| 5 |
Mazieres J, Kowalski D, Luft A, et al. Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer[J]. J Clin Oncol, 2020, 38(3): 271-280.
|
| 6 |
Kenmotsu H, Yoh K, Mori K, et al. Phase Ⅱ study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease[J]. Cancer Sci, 2019, 110(12): 3738-3745.
|
| 7 |
Öjlert ÅK, Halvorsen AR, Nebdal D, et al. The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery[J]. Mol Oncol, 2019, 13(5): 1166-1179.
|
| 8 |
袁国盛，何伟猛，胡晓云，等. 卡瑞利珠单克隆抗体联合阿帕替尼二线治疗不可切除肝细胞癌的临床疗效及安全性分析：一项多中心回顾性研究[J]. 中华肝脏病杂志，2021, 29(4): 326-331.
|
| 9 |
王书航，王 洁. 2018年V3版NCCN非小细胞肺癌指南更新要点解读[J]. 华西医学，2018, 33(4): 388-392.
|
| 10 |
廖美琳，周允中. 肺癌. 第3版[M]. 上海市：上海科学技术出版社，2012: 91-92.
|
| 11 |
张百红，岳红云. 实体瘤疗效评价标准简介[J]. 国际肿瘤学杂志，2016, 43(11): 845-847.
|
| 12 |
Kohsaka S, Petronczki M, Solca F, et al. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing [J]. Future Oncol, 2019, 15(6): 637-652.
|
| 13 |
张美娟. 非小细胞肺癌患者发病危险因素的logistic回归分析[J]. 中国卫生统计，2020, 37(3): 144-146.
|
| 14 |
刘月红，蒋军红. 非小细胞肺癌患者EGFR，ALK基因突变及临床病理特征与预后的相关性研究[J]. 临床肺科杂志，2020, 25(5): 760-763,774.
|
| 15 |
Tsoukalas N, Kiakou M, Tsapakidis K, et al. PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer[J]. J BUON, 2019, 24(3): 883-888.
|
| 16 |
Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions[J]. Oncologist, 2019, 24(1): 31-41.
|
| 17 |
Chen X, Wu X, Wu H, et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase Ⅱ trial [J]. J Immunother Cancer, 2020, 8(2): 1240-1248.
|
| 18 |
孙冬梅. 盐酸埃克替尼片靶向治疗非小细胞肺癌疗效分析[J]. 河北医药，2021, 43(14): 2138-2141.
|
| 19 |
Zhang X, Qian H, Qu X, et al. Efficacy and safety of pembrolizumab/carrelizumab, alone or in combination with chemotherapy in treatment of patients with non-small cell lung cancer: A protocol for evidence-based systematic review and Bayesian network meta-analysis[J]. Med (Baltimore), 2021, 100(29): 672-679.
|
| 20 |
Liu J, Liu Q, Li Y, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase Ⅱ trial[J]. J Immunother Cancer, 2020, 8(1): 696-702.
|
| 21 |
李 群，宋 岩，王 玺，等. 紫杉醇脂质体联合奥沙利铂和替吉奥或5-氟尿嘧啶三药双周方案一线治疗晚期胃癌的疗效和安全性分析[J]. 癌症进展，2019, 17(22): 64-67,83.
|
| 22 |
吉文晶，杨全良，毕延智，等. 妇科肿瘤患者紫杉醇脂质体3周方案给药后关键药代动力学参数Tc>0.05与不良反应的相关性研究[J]. 中国肿瘤临床与康复，2019, 26(1): 20-23.
|
| 23 |
Yeh CC, Shih LJ, Chang JL, et al. Synchronous vascular endothelial growth factor protein profiles in both tissue and serum identify metastasis and poor survival in colorectal cancer[J]. Sci Rep, 2019, 9(1): 4228-4235.
|
| 24 |
Li Q, Jiang M, Han X, et al. Induction chemotherapy for unresectable Stage Ⅲ non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer[J]. J Cancer Res Ther, 2020, 16(2): 222-229.
|
| 25 |
Shen T, Zheng S, Geng L, et al. Experience with anti-PD-1 antibody，camrelizumab, monotherapy for biliary tract cancer patients and literature review[J]. Technol Cancer Res Treat, 2020, 19(3): 153-159.
|
| 26 |
Wang S, Yan B, Zhang Y, et al. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation[J]. Int J Cancer, 2019, 144(11): 2880-2886.
|